Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomy

Journal of Urology

Volumn 192, Issue 2, 2014, Pages 409-414

  Bishoff, Jay T ^a   Freedland, Stephen J ^c,d   Gerber, Leah ^c,d   Tennstedt, Pierre ^e   Reid, Julia ^b   Welbourn, William ^b   Graefen, Markus ^e   Sangale, Zaina ^b   Tikishvili, Eliso ^b   Park, Jimmy ^b   Younus, Adib ^b   Gutin, Alexander ^b   Lanchbury, Jerry S ^b   Sauter, Guido ^e   Brawer, Michael ^b   Stone, Steven ^f   Schlomm, Thorsten ^f  

^a INTERMOUNTAIN HEALTHCARE   (United States)

^b Myriad Genetic Laboratories   (United States)

^c DURHAM VA MEDICAL CENTER   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f Martini Clinic Prostate Cancer Center University Medical Center Hamburg Eppendorf ^*

Author keywords

biopsy; prognosis; prostate; prostatectomy; prostatic neoplasms

Indexed keywords

ADULT; ADVERSE OUTCOME; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CELL CYCLE PROGRESSION SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; SCORING SYSTEM; TREATMENT OUTCOME; CANCER ADJUVANT THERAPY; CELL CYCLE PROGRESSION; CONTROLLED STUDY; GLEASON SCORE; METASTASIS FREE SURVIVAL; MIDDLE AGED; NEEDLE BIOPSY; PROGNOSTIC ASSESSMENT; PROGRESSION FREE SURVIVAL; SURVIVAL TIME;

BIOPSY; PROGNOSIS; PROSTATE; PROSTATECTOMY; PROSTATIC NEOPLASMS;

AGED; BIOPSY, NEEDLE; CELL CYCLE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSTATE; PROSTATECTOMY; PROSTATIC NEOPLASMS;

PROSTATE SPECIFIC ANTIGEN;

EID: 84904268830     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2014.02.003     Document Type: Article

References (13)

1. R. Siegel, C. DeSantis, and K. Virgo et al. Cancer treatment and survivorship statistics, 2012 CA Cancer J Clin 62 2012 220
2. C.R. Pound, A.W. Partin, and J.I. Epstein et al. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control Urol Clin North Am 24 1997 395
3. H. Zincke, J.E. Oesterling, and M.L. Blute et al. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer J Urol 152 1994 1850
4. W.J. Catalona, and D.S. Smith 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer J Urol 152 1994 1837
5. M. Ohori, J.R. Goad, and T.M. Wheeler et al. Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol 152 1994 1843
6. D.M. Bolton, A. Ta, and M. Bagnato et al. Interval to biochemical recurrence following radical prostatectomy does not affect survival in men with low-risk prostate cancer World J Urol 32 2014 431
7. S.F. Shariat, P.I. Karakiewicz, and V. Margulis et al. Inventory of prostate cancer predictive tools Curr Opin Urol 18 2008 279
8. M.R. Cooperberg, S.J. Freedland, and D.J. Pasta et al. Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy Cancer 107 2006 2384
9. D.M. Latini, S.L. Hart, and S.J. Knight et al. The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance J Urol 178 2007 826
10. M.R. Cooperberg, J.P. Simko, and J.E. Cowan et al. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort J Clin Oncol 31 2013 1428
11. J. Cuzick, D.M. Berney, and G. Fisher et al. Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort Br J Cancer 106 2012 1095
12. J. Cuzick, G.P. Swanson, and G. Fisher et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study Lancet Oncol 12 2011 245
13. S.J. Freedland, L. Gerber, and J. Reid et al. Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy Int J Radiat Oncol Biol Phys 86 2013 848